Lipid-based therapies for the treatment of neurological pathologies
Neurofix is a biotechnology company founded by experienced scientists and executives. Our pipeline consists of products both at clinical and pre-clinical development stages.
Join Neurofix Pharma
Do you want to join the Spanish company that develops the first drug against spinal cord injury pain?
Get to know us and invest in science and research made in Spain by our side.
#Invierteentusneuronas | Join us, join Neurofix Pharma
NFX88, a modified oleic acid molecule, is a nonsteroidal anti-inflammatory drug with GPCR-G protein uncoupling activity.
The effects of NFX88 on hyperalgesia reduction, which is a common condition in neurological disorders and neurodegenerative diseases, will be studied. NFX88 is formulated for convenient oral administration.
A Phase 2a clinical trial for neuropathic pain in patients with spinal cord injury is currently ongoing.
NFX81 is synthetic monounsaturated fatty acid derivative which shows great potency in the treatment of spinal cord injury , achieving mobility recovery of up to 80% in animal models after 4 weeks of treatment, whereas control animals recover just 10 to 15% of their mobility.
Very promising responses has also been observed in animal models of spinal cord injury-derived neuropathic pain.
NFX91 is a “first-in-class” treatment for insomnia whose molecular structure is similar to a natural compound and therefore it is not expected to have serious side effects.